Microarray testing (array-based comparative genome hybridisation, aCGH) provides whole genome analysis at a much higher resolution than conventional karyotyping. After routine clinical and laboratory testing with negative results aCGH provides a diagnosis in about 6% of children with non-syndromal global developmental delay (GDD). For selected patients this figure could rise to 11% with low resolution …